AI Article Synopsis
- Variceal hemorrhage is a critical medical issue treated with endoscopic variceal ligation (EVL) and terlipressin, but the necessity of terlipressin after EVL is uncertain.
- In a pilot study with 74 patients, two groups received terlipressin for 2 or 5 days, while a control group received saline, showing similar rates of re-bleeding and mortality across all groups.
- The study concluded that continuing terlipressin post-EVL does not seem beneficial, as it was linked to increased adverse drug reactions and longer hospital stays, suggesting a need for further research on its efficacy.
Article Abstract
Background: Variceal hemorrhage (VH) is a medical emergency. Prompt endoscopic variceal ligation (EVL) is therapeutic. Terlipressin is used in VH and continued for 2-5 days even after EVL. As hemostasis is primarily achieved by EVL, the benefit of continuing trelipressin after EVL is unknown.
Objective: To evaluate the efficacy of continuing terlipressin after EVL to prevent re-bleed and mortality.
Methods: In this pilot study, after EVL 74 patients of VH were randomized into two treatment groups TG2 & TG5, received terlipressin (1 mg IV bolus q 4 hourly) for 2 days and 5 days respectively and one control group (TG0), received 0.9% normal saline (10 mL IV bolus q 4 hourly) and followed up for 8 weeks.
Results: A total of 9 (12.6%) patients had re-bleed with maximum 4 (5.6%) patients in TG5 group followed by 3 (4.2%) in TG2 and 2 (2.8%) in TG0 groups (P=0.670). The overall mortality was 15 (21.1%) patients, 6 (8.5%) patients in TG0 group, followed by 5 (7.0%) in TG5 and 4 (5.6%) in TG2 group (P=0.691). Adverse drug reactions were significantly higher in treatment groups with maximum 18 (24.32%) patients in TG5, followed by 8 (10.8%) in TG2 and 2 (2.7%) in TG0 groups (P=0.00). Duration of hospital stay was also significantly higher in treatment group, 6.63 (±0.65) days in TG5 followed by 3.64 (±0.57) in TG2 and 2.40 (±0.50) days in TG0 groups (P=0.00).
Conclusion: The rational for continuing terlipressin after EVL is doubtful as it didn't have any benefit for the prevention of re-bleed or mortality; rather it increased the risk of adverse drug reactions and duration of hospital stay. Further randomized clinical trials are encouraged to generate more evidence in support or against continuing terlipressin after EVL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/S0004-2803.202200001-16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a serious complication of chronic liver disease that leads to high rates of illness and death, and terlipressin, a vasopressin analog, shows promise in treating it by effectively managing blood pressure and reducing side effects during continuous infusion.
- This study evaluated the safety and effectiveness of administering terlipressin at a continuous rate of 4 mg/day in patients with HRS-AKI, involving 136 participants who were monitored for their response to treatment and side effects.
- Results indicated that 69.1% of patients experienced a reduction in serum creatinine levels, with an average treatment duration of 7.6 days, although 21.
Long-Term Continuous Terlipressin Infusion Improves Cardiac Reserve in Patients With Decompensated Cirrhosis.
Clin Gastroenterol Hepatol
August 2024
Department of Medicine, University of Melbourne, Victoria, Australia; Victorian Liver Transplant Unit, Austin Health, Heidelberg, Australia; Australian Centre for Transplantation Excellence and Research, Melbourne, Australia; Australian Cardiovascular Collaborative in Liver Transplant Medicine, Melbourne, Australia. Electronic address:
Article Synopsis
- Long-term use of terlipressin, a treatment for hepatorenal syndrome, may improve subclinical cardiac dysfunction in patients with decompensated cirrhosis, as suggested by a study of 22 patients.
- After 12 weeks of terlipressin infusion, patients showed a significant increase in cardiac output in response to stress, indicating improved cardiac reserve.
- The study found that while resting cardiac output decreased, the number of patients with impaired cardiac reserve dropped significantly, highlighting terlipressin's potential benefits in managing cardiac health in liver disease.
Letter to the Editor: Impact of long-term continuous terlipressin infusion on the liver transplant waitlist in an Australian cohort.
Liver Transpl
January 2025
Victorian Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia.
Effect of Continuous Infusion Therapy With Low-dose Terlipressin Combined With Norepinephrine on Hemodynamics, Inflammatory Markers, and Prognosis in Patients With Severe Septic Shock.
Mil Med
August 2024
Department of Cardiology, Ganzhou People's Hospital, Ganzhou, Jiangxi 341000, China.
Objective: The present study investigated the impact of continuous infusion therapy with low-dose terlipressin (TP) combined with norepinephrine on hemodynamics, inflammatory markers, and prognosis in patients with severe septic shock.
Materials And Methods: Seventy-four patients with severe septic shock were randomly assigned to either a control group (n = 37) or an observation group (n = 37). Patients in the control group received norepinephrine alone, while those in the observation group received a continuous infusion of low-dose TP in addition to norepinephrine.
Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population.
Liver Transpl
October 2024
Formerly at Department of Research & Development, Mallinckrodt Pharmaceuticals, Scientific Affairs, Bridgewater, New Jersey, USA.
Hepatorenal syndrome-acute kidney injury (HRS-AKI) is associated with significant morbidity and mortality. While liver transplantation is the definitive treatment, continuous terlipressin infusion for HRS-AKI may provide benefit and, as such, was assessed in a population composed of candidates for liver transplant (LT). Fifty hospitalized LT-eligible patients with HRS-AKI received a single bolus followed by continuous terlipressin infusion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!